This information is current as Demonstrates Steroid Sparing Activity Disease in Murine Lupus Models and Selective IRAK 4 Inhibition Attenuates

Julie A. Carman Santella, John Duncia, John Hynes, Kim W. McIntyre and Zhu, Wen-Pin Yang, Stefan Ruepp, Satheesh Nair, Joseph Li Fan, Dawn K. Stetsko, Deborah A. Holloway, Xin Li, Jun Prasad Krishnamurthy, T. Thanga Mariappan, Ajay Saxena, Ratika Srivastava, Kamala Venkatesh, Sabariya Selvam, Siva Subramani, Durga Shiv Prasad, Preethi Karunanithi, Shailesh Dudhgaonkar, Sourabh Ranade, Jignesh Nagar,

[1]  K. Kalunian,et al.  Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus , 2017, Arthritis & rheumatology.

[2]  P. Cohen,et al.  Suppression of IRAK1 or IRAK4 Catalytic Activity, but Not Type 1 IFN Signaling, Prevents Lupus Nephritis in Mice Expressing a Ubiquitin Binding–Defective Mutant of ABIN1 , 2016, The Journal of Immunology.

[3]  Bhaskar Dutta,et al.  Comprehensive RNAi-based screening of human and mouse TLR pathways identifies species-specific preferences in signaling protein use , 2016, Science Signaling.

[4]  L. Staudt,et al.  Selective interleukin-1 receptor–associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy , 2015, The Journal of experimental medicine.

[5]  Wei Tang,et al.  Toll-like receptors: potential targets for lupus treatment , 2015, Acta Pharmacologica Sinica.

[6]  T. Junt,et al.  Translating nucleic acid-sensing pathways into therapies , 2015, Nature Reviews Immunology.

[7]  D. Tulshian,et al.  Potent and Selective Amidopyrazole Inhibitors of IRAK4 That Are Efficacious in a Rodent Model of Inflammation. , 2015, ACS medicinal chemistry letters.

[8]  M. Vilardell‐Tarrés,et al.  Neutrophil gelatinase-associated lipocalin as a biomarker for lupus nephritis. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[9]  K. Hayashi,et al.  Renoprotective effects of novel interleukin-1 receptor-associated kinase 4 inhibitor AS2444697 through anti-inflammatory action in 5/6 nephrectomized rats , 2014, Naunyn-Schmiedeberg's Archives of Pharmacology.

[10]  Suzanne N. Lissenberg-Thunnissen,et al.  TLR4-mediated pro-inflammatory dendritic cell differentiation in humans requires the combined action of MyD88 and TRIF , 2014, Innate immunity.

[11]  Dong Yu,et al.  A novel antagonist of Toll-like receptors 7, 8 and 9 suppresses lupus disease-associated parameters in NZBW/F1 mice , 2013, Autoimmunity.

[12]  A. Rabson,et al.  Inhibition of type I interferon signalling prevents TLR ligand‐mediated proteinuria , 2013, The Journal of pathology.

[13]  M. Shlomchik,et al.  Signals via the adaptor MyD88 in B cells and DCs make distinct and synergistic contributions to immune activation and tissue damage in lupus. , 2013, Immunity.

[14]  J. Casanova,et al.  Experimental and natural infections in MyD88‐ and IRAK‐4‐deficient mice and humans , 2012, European journal of immunology.

[15]  A. Bowie,et al.  The interleukin-1 receptor-associated kinases: critical regulators of innate immune signalling. , 2010, Biochemical pharmacology.

[16]  V. Pascual,et al.  TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus , 2010, Nature.

[17]  Y. Lo,et al.  Helical assembly in the MyD88:IRAK4:IRAK2 complex in TLR/IL-1R signaling , 2010, Nature.

[18]  S. Akira,et al.  The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors , 2010, Nature Immunology.

[19]  Dirk E. Smith,et al.  The IL-1 family: regulators of immunity , 2010, Nature Reviews Immunology.

[20]  A. Marshak‐Rothstein,et al.  Regulation of autoreactive B cell responses to endogenous TLR ligands , 2010, Autoimmunity.

[21]  T. Matsusaka,et al.  Fibrinogen That Appears in Bowman’s Space of Proteinuric Kidneys in vivo Activates Podocyte Toll-Like Receptors 2 and 4 in vitro , 2009, Nephron Experimental Nephrology.

[22]  M. Clare-Salzler,et al.  Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases , 2009 .

[23]  J. Casanova,et al.  The Kinase Activity of IL-1 Receptor-associated Kinase 4 Is Required for Interleukin-1 Receptor/Toll-like Receptor-induced TAK1-dependent NFκB Activation* , 2008, Journal of Biological Chemistry.

[24]  H. Gram,et al.  IRAK‐4 kinase activity‐dependent and ‐independent regulation of lipopolysaccharide‐inducible genes , 2008, European journal of immunology.

[25]  R. Coffman,et al.  Treatment of lupus‐prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms , 2007, European journal of immunology.

[26]  Douglas R. McDonald,et al.  Selective predisposition to bacterial infections in IRAK-4–deficient children: IRAK-4–dependent TLRs are otherwise redundant in protective immunity , 2007, The Journal of experimental medicine.

[27]  S. Akira,et al.  Essential role of IRAK-4 protein and its kinase activity in Toll-like receptor–mediated immune responses but not in TCR signaling , 2007, The Journal of experimental medicine.

[28]  H. Gram,et al.  IRAK-4 Kinase Activity Is Required for Interleukin-1 (IL-1) Receptor- and Toll-like Receptor 7-mediated Signaling and Gene Expression* , 2007, Journal of Biological Chemistry.

[29]  J. Shupe,et al.  Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. , 2006, Immunity.

[30]  S. Akira,et al.  Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus , 2005, The Journal of experimental medicine.

[31]  S. Akira,et al.  Role of Adaptor TRIF in the MyD88-Independent Toll-Like Receptor Signaling Pathway , 2003, Science.

[32]  Virginia Pascual,et al.  Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood , 2003, The Journal of experimental medicine.

[33]  A. Al-ghonaium,et al.  Pyogenic Bacterial Infections in Humans with IRAK-4 Deficiency , 2003, Science.

[34]  T. Mak,et al.  Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4 , 2002, Nature.

[35]  S. Wasserman,et al.  Impaired cytokine signaling in mice lacking the IL-1 receptor-associated kinase. , 1999, Journal of immunology.